These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Oxaliplatin/rituximab combination in the treatment of intermediate-low grade non-Hodgkin's lymphoma of elderly patients. Addeo R; Caraglia M; Costanzo R; Faiola V; Montella L; Abbruzzese A; Del Prete S Oncol Rep; 2004 Jul; 12(1):135-40. PubMed ID: 15201974 [TBL] [Abstract][Full Text] [Related]
26. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients. Ansell SM; Geyer SM; Maurer MJ; Kurtin PJ; Micallef IN; Stella P; Etzell P; Novak AJ; Erlichman C; Witzig TE Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6056-63. PubMed ID: 17062681 [TBL] [Abstract][Full Text] [Related]
27. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients. Aydin S; Dührsen U; Nückel H Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473 [TBL] [Abstract][Full Text] [Related]
28. Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Oki Y; Ogura M; Kato H; Kikuchi A; Taji H; Kagami Y; Oshiro A; Tsujimura A; Yamamoto K; Morishima Y Cancer Sci; 2008 Jan; 99(1):179-84. PubMed ID: 17991293 [TBL] [Abstract][Full Text] [Related]
29. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. de Vos S; Goy A; Dakhil SR; Saleh MN; McLaughlin P; Belt R; Flowers CR; Knapp M; Hart L; Patel-Donnelly D; Glenn M; Gregory SA; Holladay C; Zhang T; Boral AL J Clin Oncol; 2009 Oct; 27(30):5023-30. PubMed ID: 19770386 [TBL] [Abstract][Full Text] [Related]
30. Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression. Saito B; Shiozawa E; Yamochi-Onizuka T; Adachi D; Nakamaki T; Tomoyasu S; Omine M; Mitsuya T; Takimoto M; Ota H Pathol Int; 2004 Sep; 54(9):667-74. PubMed ID: 15363034 [TBL] [Abstract][Full Text] [Related]
31. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma]. Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071 [TBL] [Abstract][Full Text] [Related]
32. Rituximab as first-line monotherapy in low-grade follicular lymphoma with a low tumor burden. Solal-Céligny P Anticancer Drugs; 2001 Jun; 12 Suppl 2():S11-4. PubMed ID: 11508931 [TBL] [Abstract][Full Text] [Related]
33. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. Gordan LN; Grow WB; Pusateri A; Douglas V; Mendenhall NP; Lynch JW J Clin Oncol; 2005 Feb; 23(6):1096-102. PubMed ID: 15657402 [TBL] [Abstract][Full Text] [Related]
34. [Use of Mabtera (rituximab) in treating patients with refractory courses of B-cell lymphoma, along with high-dose chemotherapy and autologous transplantation of hematopoietic stem cells]. Ptushkin VV; Chimishkian KL; Zhukov NV; Osmanov DSh; Andreeva LIu; Tupitsyn NN; Larionova VB; Mkheidze DM; Poddubnaia NV Ter Arkh; 2003; 75(1):65-8. PubMed ID: 12652962 [TBL] [Abstract][Full Text] [Related]
35. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Khan KD; Emmanouilides C; Benson DM; Hurst D; Garcia P; Michelson G; Milan S; Ferketich AK; Piro L; Leonard JP; Porcu P; Eisenbeis CF; Banks AL; Chen L; Byrd JC; Caligiuri MA Clin Cancer Res; 2006 Dec; 12(23):7046-53. PubMed ID: 17145827 [TBL] [Abstract][Full Text] [Related]
36. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. Advani A; Coiffier B; Czuczman MS; Dreyling M; Foran J; Gine E; Gisselbrecht C; Ketterer N; Nasta S; Rohatiner A; Schmidt-Wolf IG; Schuler M; Sierra J; Smith MR; Verhoef G; Winter JN; Boni J; Vandendries E; Shapiro M; Fayad L J Clin Oncol; 2010 Apr; 28(12):2085-93. PubMed ID: 20308665 [TBL] [Abstract][Full Text] [Related]
37. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. Strauss SJ; Morschhauser F; Rech J; Repp R; Solal-Celigny P; Zinzani PL; Engert A; Coiffier B; Hoelzer DF; Wegener WA; Teoh NK; Goldenberg DM; Lister TA J Clin Oncol; 2006 Aug; 24(24):3880-6. PubMed ID: 16864854 [TBL] [Abstract][Full Text] [Related]
38. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. Goy A; Younes A; McLaughlin P; Pro B; Romaguera JE; Hagemeister F; Fayad L; Dang NH; Samaniego F; Wang M; Broglio K; Samuels B; Gilles F; Sarris AH; Hart S; Trehu E; Schenkein D; Cabanillas F; Rodriguez AM J Clin Oncol; 2005 Feb; 23(4):667-75. PubMed ID: 15613697 [TBL] [Abstract][Full Text] [Related]